Shopping Cart
Remove All
Your shopping cart is currently empty
ATR-IN-29, a potent, orally active inhibitor of ATR kinase, exhibits an IC50 of 1 nM and demonstrates antiproliferative activity [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | 8-10 weeks | 8-10 weeks | |
| 50 mg | Inquiry | 8-10 weeks | 8-10 weeks |
| Description | ATR-IN-29, a potent, orally active inhibitor of ATR kinase, exhibits an IC50 of 1 nM and demonstrates antiproliferative activity [1]. |
| Targets&IC50 | ATR:1 nM |
| In vitro | ATR-IN-29 (compound 1) exhibited antiproliferative activity over 4 days, with IC50 values of 156.70, 38.81, 22.48, 181.60, and 19.02 nM against A549, HCC1806, HCT116, OVCAR-3, and NCI-H460 cell lines, respectively [1]. |
| In vivo | ATR-IN-29 administered at a dose of 10 mg/kg orally once demonstrated favorable pharmacokinetic parameters in CD-1 (ICR) mice, with a half-life (t1/2) of 1.64 hours, a maximum concentration (Cmax) of 9343 ng/mL, and an area under the curve from time zero to the last measurable concentration (AUC 0-t) of 98507 ng·h/mL, as well as an area under the curve from time zero to infinity (AUC 0-inf) of 98517 ng·h/mL. |
| Molecular Weight | 378.43 |
| Formula | C19H22N8O |
| Cas No. | 2761193-67-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.